

ANJORISTM

A New Ray of Hope in Cardiac Care



Developed & Manufactured in
UK MHRA APPROVED FACILITY



Ivabradine + Metoprolol

5mg + 25mg
5mg + 50mg

7.5mg + 25mg
7.5mg + 50mg

IVABRADINE

A Cardiotonics drug that increases the efficiency and improves the contraction of the heart muscles, leading to better blood flow to the tissues of the body.

METOPROLOL

A beta blocker (medications that block the effect of epinephrine) that reduces the blood pressure by causing the heart to beat slowly.

IVABRADINE + METOPROLOL

Ivabradine and Metoprolol combination presents a novel therapeutic choice for stable coronary heart diseases.

The combination has been found effective in treatment of Angina Pectoris and Inappropriate Sinus Tachycardia (IST).



Why this combination?



1

Heart rate forms an essential consideration in coronary artery disease and its manifestations. It has been characterized to be a key target for therapy implementation.

2

Beta blockers are the most frequently used approach to control heart rate. However, recent studies continually discover lacking viability of beta-blockers in heart rate control which puts into question their adequacy, showcasing the need for an additional treatment.

3

Research has demonstrated that the addition of Ivabradine works well on patients who exhibit elevated heart rate despite being on the highest permissible quantity of Beta blockers. Ivabradine works differently from Beta Blockers.

4

Ivabradine, although as effective as beta blockers, is used for symptomatic management. Beta blockers such as Metoprolol improve survival by working to prevent heart attack.

5

Hence, the combination of Ivabradine and Metoprolol offers a new ray of hope in cardiac care.

Applications of Iva + Met Fixed Dose Combination


Stable Angina Pectoris

- Found to reduce heart rate and angina symptoms
- Shown effective reduction in heart rate with 8 fold decrease in weekly angina attacks
- Nearly 87% decrease on average nitrate consumption
- Improved results with number of patients doubling in the benign Canadian Cardiovascular Society class I



Reduction in Use of Nitroglycerin

Ivabradine and Metoprolol combination has proven to minimize the use of Nitroglycerin in patients with stable angina and CAD and a better quality of life.



Inappropriate Sinus Tachycardia (IST):

Shows significant lower Heart Rate during daily activity (as compared to monotherapy with Beta-Blocker)



Highly effective for the Elderly


- Studies show that Angina attacks in elderly (aged ≥ 75) was reduced by nearly 75%.
- Studies also conclude that the average consumption of short acting nitrates was reduced by nearly 82%.



Authorized by the European Union, this finds application worldwide in countries such as France, Germany, Italy, Austria, Bulgaria, Croatia, Czech Republic, Cyprus, Denmark, Estonia, Finland, Greece, Hungary, Latvia, Lithuania, Malta, Netherlands, Norway, Poland, Romania, Slovakia, Slovenia & Sweden.



www.archimedis.global



ANJORISTM

ARCHIMEDIS HEALTHCARE PRIVATE LIMITED

PLOT # C-27, SIPCOT INDUSTRIAL PARK, IRUNGATTUKOTTAI, SRIPERUMPUDUR,
TAMILNADU, INDIA - 602117.

WWW.ARCHIMEDIS.GLOBAL

Disclaimer: The studies referenced in this booklet are obtained from publicly available information. Archimedis Healthcare Private Limited is not responsible for any claims stated herein. Anjoris is a prescription drug and can only be sold and consumed after consulting a qualified physician. .